In 440 Japanese patients with resected biliary tract cancer, adjuvant S-1 improved 5-year overall survival versus observation (64% vs 52%; HR 0.72, 95% CI 0.55–0.95) at final prespecified follow-up; median OS 8.2 vs 5.9 years.
RCTn = 440
Ikeda et al. Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer